Preauthorization Slows Treatment; Taxing Cancer Away; HPV Saliva Test

Prescriptions for most anticancer drugs require prior authorization, which increases the time until patients begin receiving the drugs. (ASCO Quality Care Symposium)

Exelixis announced FDA approval of cabozantinib (Cabometyx) for children and adults with radioactive iodine-refractory, locally advanced/metastatic differentiated thyroid cancer previously treated with VEGF receptor-targeted therapy.

Seagen and Genmab announced FDA accelerated approval of tisotumab vedotin (Tivdak) for recurrent/metastatic cervical cancer previously treated with chemotherapy.

Doubling taxes on alcohol could reduce consumption and substantially reduce the number of alcohol-related cancers and cancer deaths. (Lancet Regional Health)

The FDA authorized a form of artificial intelligence to aid pathologists in evaluating prostate biopsies for cancer.

Incyte announced FDA approval of ruxolitinib (Jakafi) for chronic graft-versus-host disease.

Triple-negative breast cancer — the most aggressive and difficult-to-treat breast cancer — occurs three times as often in Black women as in white women. (Penn Medicine, Cancer Medicine)

A simple saliva test has shown promise as an aid to early diagnosis of oropharyngeal cancer associated with human papillomavirus. (Journal of Molecular Diagnostics)

Radiation therapy for cancer in the left breast more than doubled women’s risk of developing coronary artery disease. (JACC: CardioOncology)

Men with prostate cancer value careful, timely, and sensitive communication from healthcare providers, according to a survey of patients and their caregivers. (European Journal of Cancer Care)

A Delaware judge ruled that Japanese pharma giant Takeda broke a contract with AbbVie by not supplying the U.S. partner with the prostate cancer drug leuprolide as stipulated in the contract. (FiercePharma)